The value of the PCA3 Assay in guiding decision in which men with a previous negative prostate biopsy, a new repeat biopsy is needed: preliminary European data

Haese A, Van Poppel H, Marberger M, Mulders P, Abbou CC, Boccon-Gibod L, Stenzl A, Huland H, de la Taille A, Schalken J.
Eur Urol Suppl 2007;6(2):48 (abs. 101)

• This abstract was presented as a poster at the 22nd European Association of Urology (EAU) congress, 21-24 March 2007, Berlin, Germany.
• This preliminary analysis of a European study in 199 men with 1-2 negative biopsies confirmed the clinical utility of the PCA3 Score in guiding decision which men need repeat biopsy.
  
• In total, 25% of men had a positive repeat biopsy.
  
• The repeat biopsy rate increased with higher PCA3 Scores (Figure).
  
• Men with a PCA3 Score < 35 had a decreased likelihood of a positive biopsy (16%); men with a PCA3 Score ≥ 35 a 2.5-fold increased likelihood (41%).

Reviewed by

Prof. J. Schalken, Prof. B. Tombal, Prof. H. Van Poppel

Download

View & download Poster